Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors

Major Program(s) or Research Group(s)

  • Community Oncology and Prevention Trials
  • NCI Community Oncology Research Program
  • Supportive Care and Symptom Management

Sponsor

Southwest Oncology Group

Status

Recruiting

ClinicalTrials.gov ID

For more information, see ClinicalTrials.gov NCT03887702

This phase III trial studies how well tenofovir alafenamide works in preventing liver complications in participants with current or past hepatitis B virus (HBV) who are receiving anti-cancer therapy for solid tumors. People with chronic or past HBV who are undergoing therapy for cancer are at an increased risk for changes in the liver which could be minor or severe. Tenofovir alafenamide is a drug that acts against infections caused by HBV and may help reduce the chance that HBV gets worse or comes back in participants receiving anti-cancer therapy for solid tumors.

Intervention

Best Practice, Entecavir, Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate

Condition

Hepatitis B Virus Positive, Malignant Solid Neoplasm

Investigators

Jessica P Hwang, Jay W. Carlson, Gary L. Buchschacher, Jennifer M. Suga, Lisa Bailey, Pankaj Gupta, Irene Kang, Howard A. Zaren, Jeffrey L. Berenberg, John M. Schallenkamp, Priyank P. Patel, Mary F. Mulcahy, David M. King, John C. Henegan, Rachael A. Safyan, Jessica P. Hwang

See list of participating sites